ABSTRACT
INTRODUCTION
Prenatal diagnosis is routinely offered to all pregnant women in developed countries who have an increased risk of carrying a child with a chromosomal abnormality. Amniocentesis is the most commonly used invasive prenatal diagnostic procedure worldwide and is performed in one in 30 pregnancies in developed countries 1, 2 .
Karyotyping detects fetal chromosomal abnormalities in amniotic fluid cells 3, 4 . It is a robust technique and detects a range of numerical and structural chromosomal abnormalities with high accuracy (99.4-99.9%) 3, 5, 6 . However, due to the required fetal cell culture, karyotyping is time consuming and labor-intensive leading to high costs. The detection capacity of karyotyping may be perceived as a disadvantage as it detects chromosomal abnormalities with unclear or mild clinical relevance. The latter can cause patient anxiety, emotional dilemmas concerning the continuation of pregnancy in situations in which the outcome is uncertain or the phenotype predicted to be relatively mild 7 .
In the last decade new molecular techniques have become available for rapid aneuploidy detection of the most common chromosome abnormalities (aneuploidies of chromosomes X, Y, 13, 18 and 21). Multiplex Ligation-dependent Probe Amplification (MLPA) is a rapid high-throughput technique shown to be robust in a preclinical setting 8, 9 . MLPA avoids the detection of abnormalities with unclear clinical relevance.
If under standard clinical conditions MLPA can accurately and rapidly detect aneuploidies of chromosomes X, Y, 13, 18 and 21, it would be a suitable test for routine diagnostic application in prenatal diagnosis. Therefore, we conducted a nationwide prospective study in which we compared MLPA with karyotyping in routine clinical practice and evaluated the cost differences of both techniques. We hypothesized that MLPA has equivalent diagnostic accuracy in detecting aneuploidies of chromosomes 21, 13, 18, X and Y at lower costs.
MATERIALS AND METHODS
The M.A.K.E. (MLPA And Karyotyping, an Evaluation) study was a prospective multicentre diagnostic cohort study, comparing MLPA on amniotic fluid in a routine clinical setting with karyotyping (10). All eight Dutch prenatal diagnostic centers and their affiliated hospitals participated. The Institutional Review Boards approved the study and all participating women gave written informed consent.
We consecutively included pregnant women from March 2007 to October 2008. Pregnant women were eligible for study participation if they had a singleton pregnancy and chose to undergo amniocentesis for advanced maternal age (36 years or older), increased risk of Down syndrome following prenatal screening or parental anxiety. We excluded women with other indications for amniocentesis since they have an increased risk of chromosomal abnormalities other than the most common aneuploidies which MLPA cannot detect and karyotyping is mandatory; ultrasound abnormalities including a nuchal translucency measurement of 3.5 mm, a parental chromosomal abnormality, or a previous child with a chromosomal abnormality.
In all centers experienced maternal fetal medicine specialists performed amniocentesis following national guidelines 11 . Samples were included if the aspirated volume was at least 14 ml, leaving sufficient amniotic fluid available for MLPA analysis. No extra amniotic fluid was withdrawn in favor of the study.
For the MLPA procedure, DNA was isolated from 1 to 8 ml uncultured amniotic fluid samples, depending on the total amount of amniotic fluid received. We used a commercially available kit, the SALSA MLPA P095 (MRC Holland, the Netherlands). For each genomic target, a set of 2 probes is designed to hybridize immediately adjacent to each other on the same target strand. Both probes consist of a short target sequence and a universal polymerase chain reaction (PCR) primer-binding site. One of the probes contains a stuffer sequence with a unique length and sequence. Following hybridization, each pair of adjacent probes is joined by a ligation reaction. Next, PCR is performed using a fluorescent-labeled primer pair, which ensures that the relative yield of each of the PCR products is proportional to the amount of each of the target sequences. The different length products are separated on an automated capillary sequencer. The size and peak areas for each probe are quantified and analyzed by data analyzing software (GeneMarker, SoftGenetics, LLC, State College, PA, USA or Genescan and Genemapper version 3.7/4.0, Applied Biosystems, CA, USA) (8) . Relative probe signals are calculated and compared with samples of normal male and female sex. In chromosomally normal samples, the relative probe signal is expected to be 1 for all probes. A normal value is defined as a relative probe signal between 0.7 and 1.3. A relative probe value of <0.7 indicates a monosomy, whereas a relative probe value of >1.3 indicates a trisomy. MLPA is not expected to detect low grade chromosomal mosaicism 9, 12 .
Technicians had a molecular genetics or a cytogenetics background; all were trained in the execution of MLPA prior to the study onset. MLPA was performed in duplicate, provided We allowed a phase 1 (median time 6 months) in which test results were not reported to patients and centers could train extra personnel for sample identification, tracking and accurate reporting of test results. In phase 2 conclusive MLPA results were reported to pregnant women as a provisional result, awaiting the definite karyotype result. Patients were also informed if MLPA failed. For karyotyping, fetal cells were cultured and spread on slides, which were stained for chromosomal banding. Routinely, metaphases for 10 colonies were investigated. All centers followed national quality guidelines but minor differences in the amount of cell colonies cultured, staining and reporting of the results were allowed 13 .
The primary outcome variable was diagnostic accuracy for detecting aneuploidies of chromosomes 21, 13, 18, X and Y. We quantified the other chromosomal abnormalities that were not detected by MLPA and recorded reasons for failed test results. Turnaround time for test results was measured on laboratory level (time span between carrying out the amniocentesis and authorization of test result) and, in phase 2, on patient level (time span between amniocentesis and the result given to the patient).
Mean cost differences between MLPA and karyotyping as standalone strategies were evaluated according to international guidelines 14, 15 . Costs per strategy were calculated as the sum of resource use between amniocentesis and the decision to continue or terminate pregnancy, using individual data from the case record forms and direct observations in three centers, multiplied by resource unit prices, covering for personnel costs, equipment, consumables, additional costs in case of chromosomal abnormality, and overhead costs.
Costs were calculated in Euros and then converted into U.S. dollars (€1.00 = U.S. $1.37).
Sample size was estimated to demonstrate noninferiority of the index test (MLPA) to karyotyping. During a pre-trial meeting, experts in prenatal diagnosis, clinical epidemiology and statistics agreed on a critical noninferiority margin of 0.002. At least 4497 paired test results were needed (one-sided alpha 0.05, power 0.90), to reject the null hypothesis that MLPA is inferior to karyotyping. We calculated diagnostic accuracy by dividing the sum of the true positive and true negative results by the total number of participants. Sensitivity and specificity were calculated by standard formulas for binominal proportions; 95 percent confidence intervals were calculated by the Wilson interval method 16, 17 . Failed results were expressed in absolute numbers and percentages. To identify patient, procedural and centrespecific characteristics associated with failure rate, we performed backward-selection logistic regression analysis. Differences in costs were tested with Student's t-tests (SPSS version 16.0).
Differences in turnaround time for test results were compared with a Kruskal-Wallis followed by the post hoc Dunn's test.
RESULTS
In total 4648 women were eligible and 64 (1.4%) were excluded; 4585 amniotic fluid samples were tested with both MLPA and karyotyping (figure 1). The laboratory results of 280 women were published before (18 (table 4 and table 5 ). Diagnostic accuracy of MLPA was 1.0 (95% confidence interval (CI) 0.99 to 1.0) with a sensitivity of 100% (95% CI 0.96-1.0) and a specificity of 100% (95% CI 0.999 to 1.0). Therefore, we rejected the null hypothesis that MLPA is inferior to karyotyping (P< 0.001).
In 75 cases (1.6%) the MLPA test result failed. Karyotyping failed in one of these 75 cases (0.02%). The failure rate of MLPA was 2.4% in the first four months of the study, thereafter decreasing to 1.5% in the last 11 months. Variables significantly associated with increasing failure rate were: contaminated amniotic fluid (odds ratio (OR) 5.29 95% CI 2.4 to 11.6) and 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Obtained test results % Time (days) 
DISCUSSION
In this nationwide prospective cohort study including more than 4500 women, we demonstrated that diagnostic accuracy of MLPA to detect aneuploidies of chromosomes 21, 13, 18, X and Y is comparable to karyotyping and MLPA is less costly than karyotyping. more suitable for high-throughput testing at lower costs 22 . Therefore, QF-PCR and MLPA represent the preferred techniques for routine prenatal diagnosis. FISH, however, is preferred if chromosomal mosaicism is suspected, as detection levels of 5% can be achieved 23 .
Our study showed lower costs of MLPA compared to karyotyping; however, similar to studies on QF-PCR and FISH, considerable variation among laboratories exists, mainly caused by differences in sample throughput and logistics 22 . Further research is warranted to determine the additional costs accrued by life time costs of chromosomal abnormalities.
The failure rate of 1.6%, similar to previous studies 12, 19, 20 , is a concern. In a standalone policy, failure implies repeating the amniocentesis with its inherent risks. It is likely that the true failure rate in a standalone policy is lower. Firstly, there was a 38% reduction of the failure rate (from 2.4 % to 1.5%) between early and later experience with the test. Secondly, the study protocol prioritized karyotyping, which requires 12 ml of amniotic fluid. In a standalone policy, more amniotic fluid is available for MLPA and the failure rate will fall. Thirdly, a further decrease of failure may occur when a lower number of bloody samples can be achieved.
The American College of Obstetricians and Gynecologists recommends continuously visualizing the needle for this purpose 27 . From our study results and the available evidence, we recommend using the single operator technique with continuous ultrasound control.
Furthermore, there are two options to manage macroscopically blood-stained samples; one is to detect the proportion of fetal hemoglobin (HbF) versus adult hemoglobin and perform MLPA if the HbF level is ≥ 85% of the total hemoglobin 20 , or to omit MLPA and perform karyotyping on these samples. Finally, in a standalone policy, we recommend short-term storage of AF cells to allow karyotyping should MLPA fail and subsequent storage of DNA to allow follow-up molecular diagnostics without repeated amniocentesis should ultrasound examination show an abnormality.
The main argument against replacing karyotyping by rapid aneuploidy detection is that some clinically severe chromosomal abnormalities will remain undetected. Of the 26 chromosomal abnormalities (out of 4585; 0.6%) which MLPA could not detect, 17 were without clinical consequences for the current pregnancy (see table 5 ). Of these, 14 were inherited balanced rearrangements, which may lead to future unbalanced rearrangements.
Six of the remaining nine abnormalities were chromosomal abnormalities with uncertain clinical consequences. If detected, this type of abnormality leads to difficult counseling issues and emotional dilemmas 7 . It is questionable whether their detection is in the best interest of the parents as it may lead to an unwarranted termination of pregnancy 1, 28 . The last three chromosomal abnormalities were of serious clinical significance (see table 5 ); this overall residual risk of 0.07% confirms findings by others 1, 21 . In our study, with knowledge of the karyotype, standard follow-up ultrasound examination showed abnormalities in one out of three. Hence, when using standalone MLPA combined with ultrasound examination, two chromosomal abnormality of serious clinical significance remain undetected. In total, three of the 26 pregnancies were terminated (one of uncertain clinical consequence, two of serious clinical significance) and 23 were continued. Therefore, in our sample of 4585 pregnancies, the added knowledge from karyotyping leads to three extra terminations of pregnancy.
The provision of rapid, unambiguous and low cost results is an incentive to implement MLPA. Successful implementation also requires the support of pregnant women 29 . So far two studies show that pregnant women prefer rapid aneuploidy detection over karyotyping 22, 30 .
A Swedish study showed that 70% of women offered an actual choice preferred rapid testing over karyotyping 31 . At the public health level these studies suggest that rapid testing is the preferred strategy. If one adheres to individual choice, one could argue that the decision to either obtain as much cytogenetic information as possible versus a rapid specific result is most appropriately made by individuals who will bear the responsibility of raising the child.
In this era of rapid developments in prenatal diagnosis, the debate on what to test for remains essential. At present, the use of micro arrays, which can detect even more chromosomal abnormalities than karyotyping, is being studied 32 . Within a few years, non-invasive diagnosis of fetal chromosomal abnormalities in maternal blood may be available 33 , excluding the procedure-related miscarriage risk. Even with these new developments, the debate on targeted or whole genome testing remains in force. The widespread introduction of molecular tests changes the scope of prenatal diagnosis and should encourage the development of strategies that tailor the type of diagnostic test offered to the risk identified. Future studies should focus on the application of tailor-made strategies, including the views of pregnant women and possible barriers that hamper successful implementation of new prenatal test strategies. For now, the use of MLPA in prenatal diagnosis appears a prudent strategy.
